Sulphonylureas and hypoglycaemia.
作者信息
Ferner R E, Neil H A
机构信息
Wolfson Unit of Clinical Pharmacology, Royal Victoria Infirmary, Newcastle upon Tyne.
出版信息
Br Med J (Clin Res Ed). 1988 Apr 2;296(6627):949-50. doi: 10.1136/bmj.296.6627.949.
Abstract
摘要
相似文献
1
Sulphonylureas and hypoglycaemia.磺脲类药物与低血糖症
Br Med J (Clin Res Ed). 1988 Apr 2;296(6627):949-50. doi: 10.1136/bmj.296.6627.949.
2
Factitious hypoglycaemia.人为性低血糖症
Intern Med J. 2009 Dec;39(12):e15-7. doi: 10.1111/j.1445-5994.2009.02100.x.
3
Octreotide treatment for sulfonylurea-induced hypoglycaemia.奥曲肽治疗磺脲类药物引起的低血糖症。
Med J Aust. 2004 May 17;180(10):540-1; author reply 541. doi: 10.5694/j.1326-5377.2004.tb06064.x.
4
Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis.二肽基肽酶-4抑制剂添加至磺脲类药物与低血糖风险：系统评价和荟萃分析
BMJ. 2016 May 3;353:i2231. doi: 10.1136/bmj.i2231.
5
Sulphonylurea-induced hypoglycaemia in type 2 diabetes mellitus: a review.2型糖尿病中磺脲类药物所致低血糖症：综述
Diabetes Obes Metab. 1999 Jul;1(4):199-206. doi: 10.1046/j.1463-1326.1999.00031.x.
6
Higher incidence of severe hypoglycaemia leading to hospital admission in Type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas.与使用短效磺脲类药物治疗的2型糖尿病患者相比，使用长效磺脲类药物治疗的患者因严重低血糖导致住院的发生率更高。
Diabet Med. 1999 Jul;16(7):586-90. doi: 10.1046/j.1464-5491.1999.00110.x.
7
Inclusion of the EXAMINE study in a meta-analysis of the addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia.将EXAMINE研究纳入对磺脲类药物加用二肽基肽酶-4抑制剂与低血糖风险的荟萃分析。
BMJ. 2016 Jun 7;353:i3186. doi: 10.1136/bmj.i3186.
8
Long-acting sulfonylureas -- long-acting hypoglycaemia.长效磺脲类药物——长效低血糖症。
Med J Aust. 2004 Jan 19;180(2):84-5.
9
Sulphonylurea-induced hypoglycaemia in institutionalized elderly in Hong Kong.香港养老院中磺脲类药物所致低血糖症
Diabet Med. 2002 Nov;19(11):966-8. doi: 10.1046/j.1464-5491.2002.00807_1.x.
10
Diagnosis and treatment of sulfonylurea-induced hyperinsulinemic hypoglycemia.磺脲类药物所致高胰岛素血症性低血糖症的诊断与治疗
Am J Emerg Med. 1997 Jan;15(1):95-6. doi: 10.1016/s0735-6757(97)90062-0.
引用本文的文献
1
Treatment for childhood type 2 diabetes.儿童2型糖尿病的治疗。
Clin Pediatr Endocrinol. 2005;14(1):1-9. doi: 10.1297/cpe.14.1. Epub 2005 Feb 14.
2
Optimal management of type 2 diabetes in patients with increased risk of hypoglycemia.低血糖风险增加的2型糖尿病患者的优化管理。
Diabetes Metab Syndr Obes. 2014 Mar 6;7:85-94. doi: 10.2147/DMSO.S48896. eCollection 2014.
3
Death during intensive glycemic therapy of diabetes: mechanisms and implications.糖尿病强化血糖治疗期间的死亡：机制与影响
Am J Med. 2011 Nov;124(11):993-6. doi: 10.1016/j.amjmed.2011.08.008.
4
Disorders of glucose metabolism-post mortem analyses in forensic cases: part I.葡萄糖代谢紊乱-法医案例的死后分析：第一部分。
Int J Legal Med. 2011 Mar;125(2):163-70. doi: 10.1007/s00414-010-0509-6. Epub 2010 Sep 29.
5
Pharmacological properties and functional role of Kslow current in mouse pancreatic beta-cells: SK channels contribute to Kslow tail current and modulate insulin secretion.小鼠胰腺β细胞中缓慢失活钾电流的药理学特性及功能作用：小电导钙激活钾通道对缓慢失活钾尾电流有贡献并调节胰岛素分泌。
J Gen Physiol. 2005 Oct;126(4):353-63. doi: 10.1085/jgp.200509312.
6
Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent.那格列奈的临床药代动力学：一种吸收迅速的短效促胰岛素分泌剂。
Clin Pharmacokinet. 2004;43(2):97-120. doi: 10.2165/00003088-200443020-00003.
7
Screening for sulphonylureas in the investigation of hypoglycaemia.低血糖症调查中磺脲类药物的筛查。
J R Soc Med. 2002 Aug;95(8):381-5. doi: 10.1258/jrsm.95.8.381.
8
Appropriate timing of glimepiride administration in patients with type 2 diabetes millitus: a study in Mediterranean countries.2型糖尿病患者中格列美脲给药的适宜时间：在地中海国家开展的一项研究
Endocrine. 2000 Aug;13(1):117-21. doi: 10.1385/ENDO:13:1:117.
9
A rational approach to drug therapy of type 2 diabetes mellitus.2型糖尿病药物治疗的合理方法。
Drugs. 2000 Jul;60(1):95-113. doi: 10.2165/00003495-200060010-00006.
10
Drug interactions, renal impairment and hypoglycaemia in a patient with Type II diabetes.2型糖尿病患者的药物相互作用、肾功能损害及低血糖症
Br J Clin Pharmacol. 1999 Aug;48(2):134-7. doi: 10.1046/j.1365-2125.1999.00996.x.
本文引用的文献
1
Long-term comparative trial of glibenclamide and chlorpropamide in diet-failed, maturity-onset diabetics.格列本脲与氯磺丙脲治疗饮食控制无效的成年型糖尿病的长期对比试验
Lancet. 1975 Feb 1;1(7901):246-8. doi: 10.1016/s0140-6736(75)91141-1.
2
Insulin-induced hypoglycaemia in an accident and emergency department: the tip of an iceberg?急诊科中的胰岛素所致低血糖：冰山一角？
Br Med J (Clin Res Ed). 1982 Oct 23;285(6349):1180-2. doi: 10.1136/bmj.285.6349.1180.
3
Pharmacokinetics of intravenous glibenclamide investigated by a high performance liquid chromatographic assay.采用高效液相色谱法测定静脉注射格列本脲的药代动力学。
Diabetologia. 1982 Jul;23(1):37-40. doi: 10.1007/BF00257728.
4
Metformin and glibenclamide: comparative risks.二甲双胍与格列本脲：比较风险
Br Med J (Clin Res Ed). 1984 Aug 4;289(6440):289. doi: 10.1136/bmj.289.6440.289.
5
The control of 86Rb efflux from rat isolated pancreatic islets by the sulphonylureas tolbutamide and glibenclamide.磺脲类药物甲苯磺丁脲和格列本脲对大鼠分离胰岛中86Rb外流的控制。
Br J Pharmacol. 1984 Jul;82(3):689-700. doi: 10.1111/j.1476-5381.1984.tb10808.x.
6
Plasma levels of glibenclamide in diabetic patients during its routine clinical administration determined by a specific radioimmunoassay.
Horm Metab Res. 1983 Sep;15(9):425-8. doi: 10.1055/s-2007-1018746.
7
Glibenclamide-associated hypoglycaemia: a report on 57 cases.格列本脲相关性低血糖症：57例报告
Diabetologia. 1983 Jun;24(6):412-7. doi: 10.1007/BF00257338.
8
Effects of charcoal, sodium bicarbonate, and ammonium chloride on chlorpropamide kinetics.
Clin Pharmacol Ther. 1983 Mar;33(3):386-93. doi: 10.1038/clpt.1983.50.
9
Hypoglycaemia.
Clin Endocrinol Metab. 1980 Nov;9(3):461-75.
10
Glibenclamide is exceptional among hypoglycaemic sulphonylureas in accumulating progressively in beta-cell-rich pancreatic islets.在降血糖的磺脲类药物中，格列本脲与众不同，它会在富含β细胞的胰岛中逐渐蓄积。
Acta Endocrinol (Copenh). 1984 Mar;105(3):385-90. doi: 10.1530/acta.0.1050385.
Zotero 插件